Related references
Note: Only part of the references are listed.Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial
Lorenz Raber et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Stephen J. Nicholls et al.
JACC-CARDIOVASCULAR IMAGING (2022)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Cardiovascular disease burden: Italian and global perspectives
Andrea Saglietto et al.
MINERVA CARDIOLOGY AND ANGIOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Reducing residual cardiovascular risk with novel therapies
Michael H. Davidson
CURRENT OPINION IN LIPIDOLOGY (2020)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canakinumab for secondary prevention of atherosclerotic disease
Davide Capodanno et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering A Systematic Review and Meta-analysis
Eliano P. Navarese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Stefan M. Nidorf et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
J Stamler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
